The Ethanolic Extract of Trichosanthes Kirilowii Root Exerts anti-Cancer Effects in Human Non-Small Cell Lung Cancer Cells Resistant to EGFR TKI

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563–79. doi:10.1158/1055-9965.EPI-19-0221
   PubMed Web of Science ®Google Scholar
• Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H, Ren-Heidenreich L, Shi B, Ren H, Chu X, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer. 2014;110(11):2812–20. doi:10.1038/bjc.2014.210.
   PubMed Web of Science ®Google Scholar
• Marino FZ, Bianco R, Accardo M, Ronchi A, Cozzolino I, Morgillo F, Rossi G, Franco R. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. Int J Med Sci. 2019;16(7):981–9. doi:10.7150/ijms.34739.
   PubMed Web of Science ®Google Scholar
• Gibelin C, Couraud S. Somatic alterations in lung cancer: Do environmental factors matter? Lung Cancer. 2016;100:45–52. doi:10.1016/j.lungcan.2016.07.015.
   PubMed Web of Science ®Google Scholar
• D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. JCO. 2011;29(15):2066–70. doi:10.1200/JCO.2010.32.6181
   PubMed Web of Science ®Google Scholar
• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. doi:10.1056/NEJMoa0810699
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Gomez RG, Pallares C, Sanchez JM, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. doi:10.1016/S1470-2045(11)70393-X
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JCH, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34. doi:10.1200/JCO.2012.44.2806.
   PubMed Web of Science ®Google Scholar
• Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl_1):i10–i19. doi:10.1093/annonc/mdx703.
   PubMed Web of Science ®Google Scholar
• Del Re M, Crucitta S, Gianfilippo G, Passaro A, Petrini I, Restante G, Michelucci A, Fogli S, de Marinis F, Porta C, et al. Understanding the mechanisms of resistance in EGFR-positive NSCLC: from tissue to liquid biopsy to guide treatment strategy. IJMS. 2019;20(16):3951. doi:10.3390/ijms20163951
   Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, FLAURA Investigators, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa1913662.
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer — new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97–105. doi:10.1038/nrc1275.
   PubMed Web of Science ®Google Scholar
• Lee H, Jeong AJ, Ye SK. Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep. 2019;52(7):415–23. doi:10.5483/BMBRep.2019.52.7.152
   PubMed Web of Science ®Google Scholar
• Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019;25(1):111–8. doi:10.1038/s41591-018-0264-7.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26(2):207–21. doi:10.1016/j.ccr.2014.05.019.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021;11(2):824–40. doi:10.7150/thno.49600.
   PubMed Web of Science ®Google Scholar
• Kim DM, Kim MJ, Moon JH, Lee EY, Hong JK, Lee S, Koh DI, Ryu YS, Kim SM, Jung SA, et al. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC. Biochem Biophys Res Commun. 2020;527(1):305–10. doi:10.1016/j.bbrc.2020.04.095.
   PubMed Web of Science ®Google Scholar
• Wang Q, Lu B, Zhang Y, Yu J, Guo J, Zhou Q, Lv H, Sun Y. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells. Hum Cell. 2021;34(6):1855–65. doi:10.1007/s13577-021-00582-4.
   PubMed Web of Science ®Google Scholar
• Minh CV, Nhiem NX, Yen HT, Kiem PV, Tai BH, Le Tuan Anh H, Hien TT, Park S, Kim N, Kim SH. Chemical constituents of Trichosanthes kirilowii and their cytotoxic activities. Arch Pharm Res. 2015;38(8):1443–8. doi:10.1007/s12272-014-0490-6.
   PubMed Web of Science ®Google Scholar
• Kim SR, Seo HS, Choi HS, Cho SG, Kim YK, Hong EH, Shin YC, Ko SG. Trichosanthes kirilowii ethanol extract and cucurbitacin D inhibit cell growth and induce apoptosis through inhibition of STAT3 activity in breast cancer cells. Evid Based Complement Alternat Med. 2013;2013:975350. doi:10.1155/2013/975350.
   PubMed Web of Science ®Google Scholar
• Ryu SY, Lee SH, Choi SU, Lee CO, No Z, Ahn JW. Antitumor activity of Trichosanthes kirilowii. Arch Pharm Res. 1994;17(5):348–53. doi:10.1007/BF02974175
   Google Scholar
• Akihisa T, Kokke WCMC, Krause JA, Eggleston DS, Katayama S-i, Kimura Y, Tamura T. [D:C-Friedo-oleana-5, 7, 9(11)-triene-3a, 29-diol], a novel triterpene from Trichosanthes kirilowii MAXIM. Chem Pharm Bull. 1992;40(12):3280–3. doi:10.1248/cpb.40.3280
   Web of Science ®Google Scholar
• Jang KC, Lee JH, Kim SC, Song EY, Ro NY, Moon DY, Um YC, Park KH. Antibacterial and radical scavenging activities of 1-C-(p-hydroxyphenyl)-glycerol from Trichosanthes kirilowii. J Appl Biol Chem. 2007;50:17–21.
   Google Scholar
• Zhao J, Ben LH, Wu YL, Hu W, Ling K, Xin SM, Nie HL, Ma L, Pei G. Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors. J Exp Med. 1999;190(1):101–doi:10.1084/jem.190.1.101.
   PubMed Web of Science ®Google Scholar
• Ku JM, Hong SH, Kim HI, Kim MJ, Kim S-K, Kim M, Choi SY, Park J, Kim HK, Kim JH, et al. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3. Phytomedicine. 2020;66:153109. doi:10.1016/j.phymed.2019.153109.
   PubMed Web of Science ®Google Scholar
• Park HJ, Park SH, Choi YH, Chi GY. The root extract of Scutellaria baicalensis induces apoptosis in EGFR TKI-resistant human lung cancer cells by inactivation of STAT3. IJMS. 2021;22(10):5181. doi:10.3390/ijms22105181
   Google Scholar
• Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30(1):87. doi:10.1186/1756-9966-30-87.
   PubMed Web of Science ®Google Scholar
• Ding X, Chi J, Yang X, Hao J, Liu C, Zhu C, Wang X, Liu X, Niu Y, Ji W, et al. Cucurbitacin B synergistically enhances the apoptosis-inducing effect of arsenic trioxide by inhibiting STAT3 phosphorylation in lymphoma Ramos cells. Leuk Lymphoma. 2017;58(10):2439–51. doi: 10.1080/10428194.2017.1289521.
   PubMed Web of Science ®Google Scholar
• Park SM, Jeon SK, Kim OH, Ahn JY, Kim CH, Park SD, Lee JH. Anti-tumor effects of the ethanolic extract of Trichosanthes kirilowii seeds in colorectal cancer. Chin Med. 2019;14:43. doi: 10.1186/s13020-019-0263-8.
   PubMed Web of Science ®Google Scholar
• Kitajima J, Tanaka Y. Studies on the constituents of trichosanthes root. I. Constituents of roots of Trichosanthes kirilowii Maxim. var. japonicum Kitam. Yakugaku Zasshi. 1989;109(4):250–5. doi: 10.1248/yakushi1947.109.4_250.
   PubMed Web of Science ®Google Scholar
• Wakimoto N, Yin D, O'Kelly J, Haritunians T, Karlan B, Said J, Xing H, Koeffler HP. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci. 2008;99(9):1793–7. doi:10.1111/j.1349-7006.2008.00899.x.
   PubMed Web of Science ®Google Scholar
• Kausar H, Munagala R, Bansal SS, Aqil F, Vadhanam MV, Gupta RC. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. Cancer Lett. 2013;332(1):35–45. doi:10.1016/j.canlet.2013.01.008.
   PubMed Web of Science ®Google Scholar
• Jiao L, Xu J, Sun J, Chen Z, Gong Y, Bi L, Lu Y, Yao J, Zhu W, Hou A, et al. Chinese herbal medicine combined with EGFR-TKI in EGFR mutation-positive advanced pulmonary adenocarcinoma (CATLA): A multicenter, randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2019;10(732):732. doi:10.3389/fphar.2019.00732.
   PubMedGoogle Scholar
• Liu ZL, Zhu WR, Zhou WC, Ying HF, Zheng L, Guo YB, Chen JX, Shen XH. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: A systematic review and meta-analysis. J Integr Med. 2014;12(4):346–58. doi:10.1016/S2095-4964(14)60034-0
   PubMedGoogle Scholar
• Kim SH, Liu CY, Fan PW, Hsieh CH, Lin HY, Lee MC, Fang K. The aqueous extract of Brucea javanica suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor. Drug Des Devel Ther. 2016;10:3599–609. doi:10.2147/DDDT.S117443.
   PubMed Web of Science ®Google Scholar
• Han SY, Zhao W, Han HB, Sun H, Xue D, Jiao YN, He XR, Jiang ST, Li PP. Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells. Oncotarget. 2017;8(34):56893–905. doi:10.18632/oncotarget.18137.
   PubMedGoogle Scholar
• Song J, Zhong R, Huang H, Zhang Z, Ding D, Yan H, Sun E, Jia X. Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells. Nutr Cancer. 2014;66(4):682–9. doi:10.1080/01635581.2014.895392.
   PubMed Web of Science ®Google Scholar
• Passaro A, Malapelle U, Del RM, Attili I, Russo A, Guerini RE, Fumagalli C, Pisapia P, Pepe F, De LC, et al. Understanding EGFR heterogeneity in lung cancer. ESMO Open. 2020;5(5):e000919. doi:10.1136/esmoopen-2020-000919.
   PubMed Web of Science ®Google Scholar
• Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, Faus-Dáder MJ, Calleja-Hernández MÁ. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics. 2015;16(16):1843–62. doi:10.2217/pgs.15.122.
   PubMed Web of Science ®Google Scholar
• Ye X, Ng CC, Wong JH, Ng TB, Chan GH, Guan S, Sha O. Ribosome-inactivating proteins from root tubers and seeds of Trichosan-thes kirilowii and other trichosanthes species. Protein Pept Lett. 2016;23(8):699–706. doi:10.2174/0929866523666160526130220.
   PubMed Web of Science ®Google Scholar
• Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep. 2005;22(3):386–99. doi:10.1039/b418841c.
   PubMed Web of Science ®Google Scholar
• Zhang M, Bian ZG, Zhang Y, Wang JH, Kan L, Wang X, Niu HY, He P. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. Mol Med Rep. 2014;10(6):2905–11. doi:10.3892/mmr.2014.2581.
   PubMed Web of Science ®Google Scholar
• Yu B, Zheng L, Tang H, Wang W, Lin Y. Cucurbitacin B enhances apoptosis in gefitinib resistant non-small cell lung cancer by modulating the miR-17-5p/STAT3 axis. Mol Med Rep. 2021;24(4):710. doi:10.3892/mmr.2021.12349
   PubMed Web of Science ®Google Scholar
• Liu P, Xiang Y, Liu X, Zhang T, Yang R, Chen S, Xu L, Yu Q, Zhao H, Zhang L, et al. Cucurbitacin B induces the lysosomal degradation of EGFR and suppresses the CIP2A/PP2A/Akt signaling axis in gefitinib-resistant non-small cell lung cancer. Molecules. 2019;24(3):647. doi:10.3390/molecules24030647
   PubMed Web of Science ®Google Scholar
• Oi T, Asanuma K, Matsumine A, Matsubara T, Nakamura T, Iino T, Asanuma Y, Goto M, Okuno K, Kakimoto T, et al. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma. Int J Oncol. 2016;49(6):2275–84. doi:10.3892/ijo.2016.3757.
   PubMed Web of Science ®Google Scholar
• Tuya N, Wang Y, Tong L, Gao W, Yu R, Xue L. Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway. Exp Ther Med. 2017;14(6):5767–72. doi:10.3892/etm.2017.5286.
   PubMed Web of Science ®Google Scholar